Table 1. Treatment with inactivated ORFV reduces HBV core antigen (HBcAg) in HBV-transgenic mice (n = 7/group).
| Treatment | placebo | iORFV D1701 | iORFV NZ2 | ||||||
| Dose [TCID50] | – | 1.5×106 | 5×105 | 1.5×105 | 5×104 | 1.5×106 | 5×105 | 1.5×105 | 5×104 |
| Mean Anti-HBcAg severity score: Nuclei | 3.0 | 2.7 | 2.1 | 2.7 | 3.0 | 3.0 | 2.7 | 2.7 | 2.3 |
| Mean Anti-HBcAgseverity score:Cytoplasm | 2.9 | 1.5 | 1.7 | 2.7 | 2.4 | 1.8 | 1.0 | 2.0 | 1.8 |
*
Scores of anti-HbcAg stain: Nuclei: grade 3: the majority of nuclei in the liver specimens revealed intense immunostaining; grade 2: the number of positive nuclei was slightly reduced predominantly at the periphery of the liver lobule; grade 1: further reduction of positive nuclei was observed. Cytoplasm: grade 3: strong staining of numerous hepatocytes was observed around the central veins; grade 2: the cytoplasmic staining was reduced; grade 1: a further reduction or even absence of cytoplasmic immunostaining was observed. The histological slides were cross-checked by an independent pathologist and the results confirmed.
The severity of HBcAG-specific stain was quantified according to a scoring from 1 to 3*.